Prof. Julia C. Tchou

University of Pennsylvania School of Medicine, USA

Email: julia.tchou@uphs.upenn.edu

Qualifications

1989 Ph.D., State University of New York

1982 B.Sc., College of Mount Saint Vincent

Publications (selected)

1. Yam M, Tchou J, English R, Highnam R, Highnam R, Roskell D, Greenall M, Brady M. A mammographic dilemma: Calcification or haemosiderin as a cause of opacities? Validation of a new digital diagnostic tool.  British Journal of Radiology 74(887): 1048-1051, Nov. 2001.
2. Tchou J, Hou N, Rademaker A, Jordan VC, Morrow M. Acceptance of tamoxifen chemo-prevention by physicians and women at risk. Cancer 100(9): 1800-1806, May 1, 2004.
3. Durduran T, Choe R, Yu G, Zhou C, Tchou JC, Czerniecki BJ, Yodh AG. Diffuse optical measurement of blood flow in breast tumors. Optics Letter 30, 2915-2917, 2005.
4. Vapiwala N, Starzyk J, Harris EE, Tchou JC, Boraas MC, Czerniecki BJ, Rosato EF, Orel SG, Solin LJ: Biopsy findings after breast conservation therapy for early-stage invasive breast cancer. International Journal of Radiation Oncology Biology Physics 2007, 69(2): 490-497.
5. Tchou J, Ward MR, Volpe P, Palma MD, Medina CA, Sargen M, Sonnad SS, Godwin AK, DalyM, Winchester DJ et al: Large genomic rearrangement in BRCA 1 and BRCA 2 and clinical characteristics of men with breast cancer in the United States. Clin Breast Cancer. 2007 Jun;7(8): 627-33.
6. Basu S, Chen W, Tchou J, Mavi A, Cermik T, Czerniecki B, Schnall M, Alavi A: Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization. Cancer 2008 Mar 1;112(5): 995-1000.
7. Weinstein SP, Orel SG, Pinnamaneni N, Tchou J, Czerniecki B, Boraas M, Rosato E, Solin LJ: Mammographic appearance of recurrent breast cancer after breast conservation therapy. Acad Radiol 2008, 15(2): 240-244.
8. Tchou J, Greshock J, Bergey MR, Sonnad SS, Sargen M, Weinstein S, Czerniecki BJ, Boraas M, Fraker DL, Rosato E et al: Method of primary tumor detection as a risk factor for local and distant recurrence after breast-conservation treatment for early-stage breast cancer. Clinical Breast Cancer 2008, 8(2): 143-148.
9. Choe R, Konecky SD, Corlu A, Lee K, Durduran T, Busch DR, Pathak S, Czerniecki BJ, Tchou J, Fraker DL, Demichele A, Chance B, Arridge SR, Schweiger M, Culver JP, Schnall MD, Putt ME, Rosen MA, Yodh AG. Differentiation of benign and malignant breast tumors by in-vivo three-dimensional parallel-plate diffuse optical tomography. J Biomed Opt. 2009 Mar-Apr;14(2): 024020.
10. Tchou J, Sonnad S, Bergey MR, Basu S, Tomaszewski J, Alavi A, Schnall M: Degree of tumor FDG uptake correlates with proliferation index in triple negative breast cancer. Mol Imaging Biol. 2010 Dec;12(6): 657-62.
11. Busch DR, Guo W, Choe R, Durduran T, Feldman MD, Mies C, Rosen MA, Schnall MD, Czerniecki BJ, Tchou J, DeMichele A, Putt ME, Yodh AG: Computer aided automatic detection of malignant lesions in diffuse optical mammography. Med Phys. 2010 Apr;37(4): 1840-9.
12. Mislowsky A, Domchek S, Stroede C, Bergey M, Sonnad S, Wu L, Tchou J: Breast cancer surgery trend changes since the introduction of BRCA1/2 mutation screening - A retrospective cohort analysis of 158 mutation carriers treated at a single institution.  Ann Surg Oncol. 2011 Mar;18(3): 745-51.
13. Tchou J, Wang, L-C, Selven B, Zhang H, Conejo-Garcia J, Borghaei H, Kalos M, Vondeheide RH, Albelda SM, June CH, Zhang PJ: Mesothelin, a novel immunotherapy target for triple negative breast cancer. Accepted for publication in Breast Cancer Research and Treatment. 2012.